Saama Launches AI Tool that Automates Data Quality Checks
Data quality co-pilot considered the first of its kind.
Saama, an artificial intelligence (AI) solutions provider, has introduced a data quality (DQ) co-pilot, a feature embedded directly into its Smart Data Quality (SDQ) tool, that quickly generates code for simple to complex, cross-domain data quality checks and tests them using generative artificial intelligence (GenAI). According to the company, the product has the potential to significantly accelerate clinical development by eliminating the need to manually program, test, and deploy data quality checks.
“Generative AI and its application in clinical data management is transforming our approach to the visualization and analysis of clinical trial data,” said Malaikannan Sankarasubbu, VP, AI Research, Saama. “The time and effort saved using Saama’s embedded DQ co-pilot is empowering clinical development by enabling faster trail setup and giving precious time back to data managers. This time can be used to support more studies and focus their talent on higher-value activities, all with the goal to get new treatments to patients more quickly.”
Reference: Saama Introduces Industry’s First Generative AI Tool to Automate Data Quality Checks. Saama. September 19, 2023. Accessed September 20, 2023. https://www.saama.com/news/saama-introduces-industrys-first-generative-ai-toolto-automate-data-quality-checks/
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.
